期刊文献+

弥漫大B细胞淋巴瘤组织中MCL-1、STAT3和p53表达变化及意义 被引量:2

下载PDF
导出
摘要 目的观察弥漫大B细胞淋巴瘤(DLBCL)组织中髓样细胞白血病基因1(MCL-1)及其相关因子信号转导和转录激活因子(STAT3)和p53的表达变化,并探讨其临床意义。方法应用免疫组化法检测75例DLBCL组织(DLBCL组)、20例反应性淋巴增生组织(对照组)中的MCL-1、STAT3、p53,分析各指标与DLBCL临床病理参数的关系。结果 DLBCL组MCL-1、STAT3、p53阳性表达率分别为61.3%、61.3%、45.3%,对照组分别为15.0%、10.0%、0,P均<0.01;生发中心(GCB)型DLBCL组织中MCL-1、STAT3和p53阳性表达率分别为33.3%、33.3%、0.09%,非GCB型DLBCL组织中分别为72.0%、69.4%、44.4%,P均<0.05;MCL-1、STAT3、p53表达与DLBCL患者的性别、年龄、发病部位无关(P均>0.05),DLBCL组织中MCL-1表达与STAT3、p53表达呈正相关(r分别为0.320、0.299,P均<0.01)。结论 DLBCL组织中MCL-1、STAT3和p53表达均升高,三者可能协同参与了DLBCL尤其是非GCB型DLBCL的发生、发展。
机构地区 天津医科大学
出处 《山东医药》 CAS 2014年第16期54-56,I0004,共4页 Shandong Medical Journal
  • 相关文献

参考文献16

  • 1Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classifi- cation of lymphoid neoplasms and beyond: evolving concepts and practical applications [ J ]. Blood, 2011,117 (19) :5019-5032. 被引量:1
  • 2Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lym-phoma by immu-nohistochemistry using a tissue microarray [ J ]. Blood, 2004,103 ( 1 ) :275-282. 被引量:1
  • 3陈鸰,汤恢焕,菅志远.PTTG在胰腺癌组织中的表达及其意义[J].中国现代医学杂志,2007,17(23):2906-2908. 被引量:3
  • 4Fujise K, Zhang D, Liu J, et al. Regulation of apoptosis and cell cycle progression by MCL-I. Differential role of proliferating cell nu- clear antigen[J]. J Biol Chem, 2000,275(50) :39458-39465. 被引量:1
  • 5Mott JL, Kobayashi S, Bronk SF, et al. Mir-29 regulates Mcl-1 protein expression and apoptosis[ J ]. Oneogene, 2007,26(42) :6133-6140. 被引量:1
  • 6Nijhawan D, Fang M, Traer E, et al. Elimination of Mcl-1 is re- quired for the initiation of apoptosis following ultraviolet irradiation [J]. Genes Dev, 2003,17(12) :1475-1486. 被引量:1
  • 7Michels J, O'Neill JW, Dallman CL, et al. Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage [ J ]. Oncogene, 2004,23 (28) :4818-4827. 被引量:1
  • 8Song L, Coppola D, Livingston S, et al. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells [ J ]. Cancer Biol Ther, 2005,4 (3) :267-276. 被引量:1
  • 9Wuilleme-Toumi S, Robillard N, Gomez P, et al. Mcl-1 is overex- pressed in multiple myeloma and associated with relapse and shorter survival [ J ]. Leukemia, 2005,19 ( 7 ) : 1248-1252. 被引量:1
  • 10Schulze-Bergkamen H, Fleischer B, Schuchmann M, et al. Sup- pression of Mcl-1 via RNA interference sensitizes human hepatocel- lular carcinoma ceils towards apoptosis induction [ J ]. BMC Canc- er, 2006(6) :232. 被引量:1

二级参考文献14

  • 1金中元,程瑞雪,郑长黎,冯德云,郑晖.PTTG基因表达在原发性肝细胞癌发生中的作用及其机制的初步研究(英文)[J].中国现代医学杂志,2004,14(24):37-40. 被引量:3
  • 2NIU G,HELLER R,CATLETT-FALCONE R,et al.Gene therapy with dominant-neagative STAT3 suppresses growth of the murine B16 tumor in vivo[J].Cancer Res,1999,59:5059-5063. 被引量:1
  • 3AKIRA S.Functional roles of STAT family proteins:lessons from knockoutmice[J].Stem Cell,1999,17:138-146. 被引量:1
  • 4DEMOULIN J B,VAN ROOST E,STEVEN M,et al.Distinct roles for STAT1,STAT3 and STAT5 in differentiation gene induction and apoptosis inhibition by interleukin-9[J].J Biol Chem,1999,274:25855 -25861. 被引量:1
  • 5MASUDA M,SUZUI M,YASUMATU R,et al.Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma[J].Cancer Res,2002,62:3351-3355. 被引量:1
  • 6TURKSON J,JOVE R.STAT proteins:novel molecular targets for cancer drug discovery[J].Oncogene,2000,19:6613-6626. 被引量:1
  • 7SCHOLZ A,HEINZE S,DETJEN K M,et al.Activated signal transducer and activator of transcription3 (STAT3) supports the mallgnant phenotype of human pancreatic cancer[J].Gastroenterology,2003,125:891-905. 被引量:1
  • 8ZHANG X, HORWITZ GA, PREZANT TR, et al. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG)[J]. Mol Endocrinol, 1999, 13(1): 156-166. 被引量:1
  • 9PEI L, MELMED S. Isolation and characterization of a pituitary tumor- transforming gene (PTrG)[J]. Mol Endocrinol, 1997, 11(4): 433-441. 被引量:1
  • 10MCCABE CJ, GITTOES NJ. PTTG-a new pituitary turnout transforming gene[J]. J Endocrinol, 1999, 162(2): 163-166. 被引量:1

共引文献18

同被引文献42

  • 1ChesonBD,BennettJM,KopeckyKJ,周学慧,肖志坚.国际工作组关于急性髓系白血病治疗试验的诊断、疗效标准的标准化、治疗结局和报告标准的修订建议[J].白血病.淋巴瘤,2004,13(4):246-250. 被引量:31
  • 2Zubair A, Fried M. Role of nuclear factor-B in breast and colorectal cancer [ J ]. Curr Allergy Asthma Rep, 2013,13 ( 1 ) :44 -49. 被引量:1
  • 3Ferrara N, Gerber HP, Hillan K J, et al. VEGF is required for growth and survival in neonatal[ J ]. Development, 1999,126 ( 6 ) : 1149-1159. 被引量:1
  • 4Yao X, Ahmadzadeh M, Lu YC, et al. Levels of peripheral CIM ( + ) Foxp3 ( + ) regulatory T cells are negatively associated with clinical re- sponse to adoptive immunotherapy of human cancer[ J ]. Blood,2012, 119 (24) :5688-5696. 被引量:1
  • 5Pooja A, Nuttapong N, Sulada P, et al. The expression of bel-6 in diffuse large B cell lymphoma(DLBCL) is associated with improved progression free survival and overall survival following front-line Rituximab-ehemo- therapy[ J. Blood( ASH Annual Meeting Abstracts) ,2010,116:5073. 被引量:1
  • 6Salles G,Morschhauser F,Lamy T,et al.Phase 1 study results of the typeⅡglycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab(GA101)in B-cell lymphoma patients[J].Blood,2012,119(22):5126-5132. 被引量:1
  • 7Ohmachi K,Niitsu N,Uchida T,et al.Multicenter phaseⅡstudy of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma[J].J Clin Oncol,2013,31(17):2103-2109. 被引量:1
  • 8Rouquette-Jazdanian AK,Kortum RL,Li W,et al.miR-155 Controls Lymphoproliferation in LAT Mutant Mice by Restraining T-Cell Apoptosis via SHIP-1/m TOR and PAK1/FOXO3/BIM Pathways[J].PLo S One,2015,10(6):e0131823. 被引量:1
  • 9Karachi A,Fazeli M,Karimi MH,et al.Evaluation of Immunomodulatory Effects of Mesenchymal Stem Cells Soluble Factors on miR-155 and miR-23b Expression in Mice Dendritic Cells[J].Immunol Invest,2015,44(5):427-431. 被引量:1
  • 10Jovanovic MP,Mihaljevic B,Jakovic L,et al.BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes[J].J BUON,2015,20(3):820-828. 被引量:1

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部